Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Additionally, the success of Libtayo in the treatment of cutaneous ... Goldman Sachs also reiterated a Buy rating on the stock with a $1,185.00 price target. TipRanks tracks over 100,000 company ...

LIBTAYO's robust efficacy in high-risk CSCC ... a substantial pullback the stock appears to be a BUY at current prices. The stock remains in a downtrend, thus dollar-cost-averaging seems desirable ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Of its remaining product sales, standouts included cancer drug Libtayo, with a robust 50% gain to $367 million. The company's collaboration revenue derived from partnerships with Sanofi and Bayer ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.